Moneycontrol
Last Updated : Feb 02, 2011 02:51 PM IST | Source: CNBC-TV18

Parabolic Drugs eyes Rs 900cr sales next year

In an interview CNBC-TV18, Vineet Gupta, Director, Parabolic Drugs, speaks about the results and gives his outlook going forward.


Parabolic Drugs Q3 revenue was up 29.8% at Rs 151.5 crore versus Rs 116.7 crore on year-on-year (YoY) basis.  Its profit after tax (PAT) was up 33.2% at Rs 12.5 crore versus Rs 9.4 crore, YoY.


In an interview CNBC-TV18, Vineet Gupta, Director, Parabolic Drugs, speaks about the results and gives his outlook going forward.


Below is a verbatim transcript of his interview with CNBC-TV18's Latha Venkatesh and Sonia Shenoy. Also watch the accompanying video.


Q: Take us through this quarter and in fact the nine months. The kind of run rate you are able to maintain in terms of 22% for the nine month and 30% for the third quarter itself. Should we assume that fourth quarter and the next couple of quarters you could up the ante and go at 30% pace?


A: Let me just take you through the nine months first. In terms of gross sales, we are up almost 25%. In terms of profit after tax, we are up almost 65%. So, our profit after tax for the nine month is close to Rs 37 crore. So, we have really surpassed the 12-month number of last year which was about Rs 34 crore. So, it has been pretty robust build up, in line with our expectations.


One of the major developments in the last quarter has been that we have commissioned a new Cephalosporin Oral plant which we call Multi Purpose Two plant. We are going to be making three drugs here. This is a large facility and this is a capacity addition of about 40% to our Cephoral capacity, so this is a fairly large volume.

Now, with this capacity our Derabassi facility, which is our Cephalosporin facility, at peak production value this facility alone has potential to do about Rs 800 crore in top-line. So, we are fairly bullish about the last quarter. With the addition in this capacity and the fact being that the last quarter is normally the best quarter in the antibiotics business, we are fairly optimistic that we should definitely be able to maintain that 25% run rate. Let

First Published on Feb 2, 2011 02:35 pm